Genentech’s tocilizumab shortage due to Covid-19 now hits CAR-T recipients, with FDA offering alternatives to help

Soon after San Francisco-based Genentech won an EUA for tocilizumab as a treatment for hospitalized Covid patients last summer, the company announced a shortage of the drug while pointing to the emergence of the Delta variant and the slowing of vaccination rates across the US.

“This new wave of the...

Click to view original post